FDA Approves Promising Weight Loss Drug, First in Years

The weight loss drug has been described as “revolutionary” by obesity researchers. In the US, more than 100 million adults – about 1 in 3 – are obese.

The United States Food and Drug Administration (FDA) approved Wegovy, a higher-dose version of Novo Nordisk’s diabetes medicine , semaglutide , forlong-term weight control.

In company-funded studies, participants who took Wegovy they lost an average of 15% of their weight, that is, about 15.3 kilograms. The participants lost weight steadily for 14 months before stagnating . In a comparison group that received sham injections, the average weight loss was 2.5%, or just under 2 kilos. 

With existing drugs, you get a weight reduction of between 5% and 10%, and sometimes not even that “says Dr. Harold Bays , medical director of the Louisville Center for Metabolic and Atherosclerosis Research. Bays, who is also the scientific director of the Obesity Medicine Association, helped lead the studies of the drug. 

Synthesized version of an intestinal hormone

Wegovy is a synthesized version of an intestinal hormone that curbs your appetite. The patientsinjected weekly under the skin. Like other weight loss drugs, It should be used in conjunction with exercise, a healthy diet, and other measures such as keeping a food diary.

Given that nearly three-quarters (73.6 percent) of American adults age 20 and older are overweight or obese, the new drug is expected to help many thousands of Americans with weight-related ailments regulate their intake. food.

Side effects and risks

Bays said Wegovy appears much safer than previous anti-obesity drugs that “have fallen out of favor” due to safety concerns.

The most common side effects of Wegovy were gastrointestinal problems, such as nausea, diarrhea, and vomiting. Although they usually remit, 5% of the study participants stopped taking it.

The drug carries a potential risk of developing a type of thyroid tumor , so it should not be taken by people with a personal or family history of certain thyroid and endocrine tumors. Wegovy also carries a risk of depression and inflammation of the pancreas. 

“This is the first time this magnitude of weight loss has been seen with a drug,” says obesity expert Robert Kushner of Northwestern University, who supervised the research.

“This approval offers people with obesity a one-time-a-week, non-surgical option with results that have never been demonstrated before with an anti-obesity drug .”

Possible high price to pay

Although Wegovy’s promise has the potential to help a large number of people control their weight, an unfortunate barrier for many will be the cost of entry.

The Danish company has not disclosed the price of Wegovy, but has said that it will be similar to that of its Saxenda, a weight loss medicine that is injected daily and that it usually costs more than $ 1,300 a month without insurance. Novo Nordisk is also developing a pill version.

 

Source: https://www.t13.cl/

Leave a Reply

Your email address will not be published. Required fields are marked *